摘要
目的探讨利培酮口服液治疗精神分裂症患者的依从性。方法把符合CCMD-3诊断标准的精神分裂症患者100例,随机分成两组,分别给予利培酮口服液(B组)和阿立哌唑(A组)治疗8周,采用简明精神症状量表(BPRS)评定疗效,副反应量表(TESS)评定副反应。比较两组的服药依从性。结果治疗8周后两组疗效差异不显著,B组药物完全依从占67.2%,显著高于A组的42.1%。不依从占3.4%,则显著低于A组的32.9%。利培酮的不良反应以锥体外系为主,阿立哌唑则以嗜睡为主,但易缓解。结论利培酮口服液能更好地提高治疗的依从性。
Objective To evaluate the compliance of Risperidone oral solution in the treatment of Schizophrenia. Methods 100 patients with Schizophrenia diagnosed according to CCMD-3 criteria were divided into two groups randomly, the patients were treated with Risperidone oral solution or Aripiprazole for 8 weeks, the efficacy was evaluated with BPRS, the side effects was evaluated with TESS, the medication compliance was compared between two groups. Results There were no significant difference in efficacy between two groups, the compliance rate in Group A was 67.2%, while it was 42. 1% in Group B, the difference was significant. The no compliance rate was 3.4% and 32.9% in Group A and B, respectively, the difference was significant. The side effect of Risperidone oral solution was extrapyramidal system syndrome,while it was drowsiness in Aripiprazole, the side effects can be relieved easily. Conclusion The compliance of Risperidone oral solution is better in the treatment of Schizophrenia.
出处
《中国实用医药》
2008年第22期51-52,共2页
China Practical Medicine
关键词
利培酮口服液
阿立哌唑
依从性
Risperidone oral solution
Aripiprazole
Compliance
